PP
MCRB icon

PDT Partners’s Seres Therapeutics MCRB Stock Holding History

PDT Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,950
Closed -$614K – 977
2022
Q2 		$614K Hold
8,950
– – 0.05% 547
2022
Q1 		$1.27M Sell
8,950
-6,083
-40% -$936K 0.11% 294
2021
Q4 		$2.5M Sell
15,033
-368
-2% -$58.5K 0.19% 194
2021
Q3 		$2.14M Buy
+15,401
New +$3.01M 0.15% 236
2017
Q3 		– Sell
-1,275
Closed -$288K – 543
2017
Q2 		$288K Sell
1,275
-412
-24% -$84.6K 0.01% 457
2017
Q1 		$380K Sell
1,687
-1,708
-50% -$347K 0.02% 403
2016
Q4 		$672K Sell
3,395
-2,335
-41% -$509K 0.04% 367
2016
Q3 		$1.41M Buy
+5,730
New +$2.01M 0.08% 266

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PDT Partners's MCRB Position: Q3 2022 in Review

PDT Partners sold out of Seres Therapeutics (MCRB) in Q3 2022, closing a stake of 8,950 shares — an estimated $614K sold.

PDT Partners first reported a position in MCRB in Q3 2016 and held it in 8 quarters. The position peaked at $2.5M in Q4 2021. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

  • PDT Partners reported no remaining Seres Therapeutics position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 8,950 Seres Therapeutics shares in Q3 2022, an estimated $614K.
  • PDT Partners first reported a position in Seres Therapeutics in Q3 2016 and held it in 8 quarters.
  • PDT Partners's Seres Therapeutics position peaked at $2.5M in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.